CNR1 and myeloid sarcoma: In the Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) model of MS, treatment with WIN 55,212–2, ACEA (a CB1 agonist), or JWH-015 (a CB2 agonist) showed a marked reduction in microglial activation visible in their morphology, as well as functional recovery in the rotarod test [227].